These findings further support B7-H3 as a bona fide therapeutic target for cancer, and studies to identify modulators of B7-H3 dimerization as an alternative interventional strategy are underway capitalizing on the high-throughput potential of using the 4Ig-B7-H3 split luciferase complementation assay. Here, CD276 is linked to cancer.